公开(公告)号：US20240150355A1

公开(公告)日：2024-05-09

申请号：US18540129

申请日：2023-12-14

申请人： ASTRAZENECA AB ,  CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Maurice Raymond Verschoyle FINLAY ,  Frederick Woolf GOLDBERG ,  Martin Richard HOWARD ,  Attilla Kuan Tsuei TING

IPC分类号： C07D473/32 ,  A61K9/127 ,  A61K31/437 ,  A61K31/502 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/704

CPC分类号： C07D473/32 ,  A61K9/127 ,  A61K31/437 ,  A61K31/502 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/704 ,  A61N5/10

摘要： The specification generally relates to compounds of Formula (I):




and pharmaceutically acceptable salts thereof, where R1, A1, A2 and A3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

公开(公告)号：US20230271949A1

公开(公告)日：2023-08-31

申请号：US18056836

申请日：2022-11-18

申请人： ASCLETIS BIOSCIENCE CO., LTD.

发明人： Bin Liang ,  Yacheng Yang ,  Peng Wang ,  Bailing Yang ,  Yang Lai ,  Jinzi J. Wu

IPC分类号： C07D405/14 ,  C07D401/10 ,  C07D401/14 ,  C07D417/14 ,  C07D487/04 ,  C07D471/08 ,  C07D471/04 ,  C07D473/32 ,  C07D409/14 ,  C07D413/14 ,  C07D495/04 ,  C07D513/04 ,  C07D498/04

CPC分类号： C07D405/14 ,  C07D401/10 ,  C07D401/14 ,  C07D417/14 ,  C07D487/04 ,  C07D471/08 ,  C07D471/04 ,  C07D473/32 ,  C07D409/14 ,  C07D413/14 ,  C07D495/04 ,  C07D513/04 ,  C07D498/04

摘要： The present application describes GLP-IR modulating compounds that are useful for treating GLP-IR-mediated diseases or conditions.

公开(公告)号：US20210163423A1

公开(公告)日：2021-06-03

申请号：US17172435

申请日：2021-02-10

申请人： NeuPharma, Inc.

发明人： Xiangping QIAN ,  Yong-Liang ZHU

IPC分类号： C07D239/84 ,  C07D473/32 ,  A61P35/00 ,  A61K31/495 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D473/30

摘要： Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

公开(公告)号：US11001559B2

公开(公告)日：2021-05-11

申请号：US16325022

申请日：2017-08-15

申请人： Purdue Research Foundation

发明人： Herman O. Sintim

IPC分类号： C07D471/04 ,  C07D401/06 ,  C07D217/22 ,  C07D401/12 ,  C07D487/04 ,  C07D417/04 ,  C07D471/10 ,  C07D473/32 ,  C07D413/04 ,  C07D239/95 ,  C07D213/73 ,  C07D239/84 ,  C07D401/04 ,  C07D403/04 ,  C07D417/12 ,  C07D401/10 ,  C07D403/10 ,  A61P35/00 ,  C07D209/49 ,  C07D221/02 ,  C07D233/10 ,  C07D271/06 ,  C07D413/06

摘要： This invention relates to 4-substituted isoquinoline compounds and their derivatives and uses thereof for treatment of cancer, for example, acute myeloid leukemia.

公开(公告)号：US10947201B2

公开(公告)日：2021-03-16

申请号：US15044966

申请日：2016-02-16

申请人： NEUPHARMA, INC.

发明人： Xiangping Qian ,  Yong-Liang Zhu

IPC分类号： C07D239/84 ,  C07D473/32 ,  A61P35/00 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D473/30 ,  A61K31/495

摘要： Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

公开(公告)号：US20200172495A1

公开(公告)日：2020-06-04

申请号：US16702936

申请日：2019-12-04

申请人： NeuPharma, Inc.

发明人： Xiangping QIAN ,  Yong-Liang ZHU

IPC分类号： C07D239/74 ,  C07D403/12 ,  A61K45/06 ,  C07D403/04 ,  C07D239/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/14 ,  C07D471/04 ,  C07D473/32 ,  C07D487/04

摘要： Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

公开(公告)号：US10646493B2

公开(公告)日：2020-05-12

申请号：US16514749

申请日：2019-07-17

申请人： Signal Pharmaceuticals, LLC

发明人： Matthew Alexander ,  Sogole Bahmanyar ,  John Frederick Boylan ,  Joshua Hansen ,  Dehua Huang ,  Robert Hubbard ,  Brandon Jeffy ,  Jim Leisten ,  Mehran Moghaddam ,  Raj K. Raheja ,  Heather Raymon ,  Kimberly Schwarz ,  Marianne Sloss ,  Eduardo Torres ,  Tam Minh Tran ,  Shuichan Xu ,  JingJing Zhao

IPC分类号： A61K31/52 ,  C07D473/32 ,  A61P35/00 ,  A61K31/5377

摘要： Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

公开(公告)号：US20190336507A1

公开(公告)日：2019-11-07

申请号：US16514749

申请日：2019-07-17

申请人： Signal Pharmaceuticals, LLC

发明人： Matthew Alexander ,  Joshua Hansen ,  Dehua Huang ,  Robert Hubbard ,  Raj K. Raheja ,  Kimberly Schwarz ,  Marianne Sloss ,  Eduardo Torres ,  JingJing Zhao ,  Shuichan Xu ,  Sogole Bahmanyar

IPC分类号： A61K31/52 ,  A61P35/00 ,  C07D473/32 ,  A61K31/5377

摘要： Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

公开(公告)号：US10420771B2

公开(公告)日：2019-09-24

申请号：US16000968

申请日：2018-06-06

申请人： Celgene Corporation

发明人： Stacie S. Canan ,  Natalie Anne Hawryluk

IPC分类号： A61K31/52 ,  G01N33/569 ,  C07D231/02 ,  C07C211/36 ,  C07C13/06 ,  C07C217/02 ,  C07D473/32

摘要： Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologs, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

公开(公告)号：US10407446B2

公开(公告)日：2019-09-10

申请号：US15846679

申请日：2017-12-19

申请人： AstraZeneca AB ,  Cancer Research Technology Limited

发明人： Maurice Raymond Verschoyle Finlay ,  Frederick Woolf Goldberg ,  Attilla Kuan Tsuei Ting

IPC分类号： A61K31/522 ,  C07D473/32 ,  C07D519/00 ,  C07D473/18 ,  A61P35/00 ,  A61K31/502 ,  A61K45/06

摘要： The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.